The primary market will see four new IPOs opening for subscription next week including three in the SME segment. Apart from these new issues, the Street will also witness 7 listings. Going forward, the primary market momentum for the rest of the year looks strong with some bankers expecting as many as 1,000 IPOs in…
READ MOREEquity indices Sensex and Nifty rebounded sharply on Monday after five days of steep decline amid value buying at lower levels and a supportive trend in global markets. Stocks that were in focus include names like SAIL, which rose 4% and Aurobindo Pharma, which gained 1% and HPCL, whose shares declined nearly 1% on Monday….
READ MOREForeign portfolio investors (FPIs) recorded net equity inflows of Rs 21,789 crore in December so far, marking a significant reversal after months of heavy outflows. With this surge in December, FPIs have experienced a total net inflow of Rs 6,770 crore in 2024, compared to outflows of Rs 15,019 crore at the end of November….
READ MOREThe 2QFY25 corporate earnings report revealed a weaker-than-expected overall performance, with Nifty earnings growing by just 4% YoY, in line with estimates. This marks the second consecutive quarter of single-digit growth for the Nifty, a trend not seen since the pandemic’s onset in June 2020. The aggregate performance was hit by a drag from global…
READ MOREGlobal brokerage firms have shared their insights on key stocks, highlighting investment opportunities with potential upsides. Goldman Sachs has reiterated its confidence in Eicher Motors and Larsen & Toubro (L&T), citing strong growth drivers and robust performance indicators. Meanwhile, UBS has maintained its bullish stance on Apollo Tyres, emphasizing a promising outlook despite mixed quarterly…
READ MOREOver the past few months, the market witnessed a sharp rally in pharma sector stocks, one of the key drivers behind this surge is ‘Patent Cliff.’ A Patent cliff occurs when a significant number of drug patents expire and other companies are allowed to manufacture similar drug. Typically, the patent of a drug lasts for…
READ MORE